Literature DB >> 18095084

Neutralization of staphylococcal exotoxins in vitro by human-origin intravenous immunoglobulin.

Chie Yanagisawa1, Hideaki Hanaki, Taiji Natae, Keisuke Sunakawa.   

Abstract

Human-origin intravenous immunoglobulin (IVIG) collected from healthy individuals was tested for its neutralizing activity against the hemolysin, toxic shock syndrome toxin-1 (TSST-1), and enterotoxins, produced by laboratory strains of methicillin-resistant Staphylococcus aureus (MRSA). The hemolytic activity of the culture supernatant against sheep red blood cells was reduced from 100% to 5.5% relative hemolysis in the presence of 0.156 mg protein/ml of IVIG. The maximum dilution endpoint of the culture supernatant for TSST-1-mediated latex aggregation was 32-fold. This level of TSST-1 activity was reduced to eightfold dilution by 0.78 mg protein/ml of IVIG, and the latex aggregation activity of undiluted TSST-1 in the culture supernatant was inhibited by 1.56 mg protein/ml of IVIG. Similarly, the enterotoxin A-mediated latex aggregation titer appeared to be a 320-fold dilution. This toxin activity was reduced to an 80-fold dilution and below a tenfold dilution by 0.049 through 0.78 and 1.56 mg protein/ml, respectively, of IVIG. These results show that IVIG has powerful neutralizing activity against hemolysin, TSST-1, and enterotoxin A. Therefore, IVIG may be useful for passive immunization therapy in patients suffering from diseases caused by MRSA exotoxins.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18095084     DOI: 10.1007/s10156-007-0551-6

Source DB:  PubMed          Journal:  J Infect Chemother        ISSN: 1341-321X            Impact factor:   2.211


  14 in total

1.  Intravenous immunoglobulin preparation attenuates LPS-induced production of pro-inflammatory cytokines in human monocytic cells by modulating TLR4-mediated signaling pathways.

Authors:  Kazuki Murakami; Chiaki Suzuki; Fujio Kobayashi; Atsushi Nakano; Akihiro Fujii; Kaoru Sakai; Teruaki Imada
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2012-05-31       Impact factor: 3.000

2.  Use of intravenous immunoglobulin in critically ill patients.

Authors:  Summer Donovan; Gonzalo M L Bearman
Journal:  Curr Infect Dis Rep       Date:  2014-12       Impact factor: 3.725

3.  Commercial Intravenous Immunoglobulin Preparations Contain Functional Neutralizing Antibodies against the Staphylococcus aureus Leukocidin LukAB (LukGH).

Authors:  James B Wood; Lauren S Jones; Nicole R Soper; Meera Nagarsheth; C Buddy Creech; Isaac P Thomsen
Journal:  Antimicrob Agents Chemother       Date:  2017-10-24       Impact factor: 5.191

Review 4.  Antibodies for biodefense.

Authors:  Jeffrey W Froude; Bradley Stiles; Thibaut Pelat; Philippe Thullier
Journal:  MAbs       Date:  2011-11-01       Impact factor: 5.857

Review 5.  Role of Host Immune and Inflammatory Responses in COVID-19 Cases with Underlying Primary Immunodeficiency: A Review.

Authors:  Benjamin M Liu; Harry R Hill
Journal:  J Interferon Cytokine Res       Date:  2020-12       Impact factor: 2.607

6.  Eradication of drug resistant Staphylococcus aureus by liposomal oleic acids.

Authors:  Chun-Ming Huang; Chao-Hsuan Chen; Dissaya Pornpattananangkul; Li Zhang; Michael Chan; Ming-Fa Hsieh; Liangfang Zhang
Journal:  Biomaterials       Date:  2010-09-28       Impact factor: 12.479

7.  Intravenous immunoglobulin prevents release of proinflammatory cytokines in human monocytic cells stimulated with procalcitonin.

Authors:  Kazuki Murakami; Chiaki Suzuki; Akihiro Fujii; Teruaki Imada
Journal:  Inflamm Res       Date:  2012-02-22       Impact factor: 4.575

8.  Assessment of the efficacy of polyclonal intravenous immunoglobulin G (IVIG) against the infectivity of clinical isolates of methicillin-resistant Staphylococcus aureus (MRSA) in vitro and in vivo.

Authors:  N Farag; L Mahran; K Abou-Aisha; M El-Azizi
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2013-03-27       Impact factor: 3.267

9.  Inhibition of toxic shock by human monoclonal antibodies against staphylococcal enterotoxin B.

Authors:  Eileen A Larkin; Bradley G Stiles; Robert G Ulrich
Journal:  PLoS One       Date:  2010-10-11       Impact factor: 3.240

Review 10.  Role of pathogens in multiple sclerosis.

Authors:  Jane E Libbey; Matthew F Cusick; Robert S Fujinami
Journal:  Int Rev Immunol       Date:  2013-11-22       Impact factor: 5.311

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.